Literature DB >> 16210460

Psychosis in Parkinson's disease.

B R Thanvi1, T C N Lo, D P Harsh.   

Abstract

Psychosis is common in Parkinson's disease (PD), particularly in its later stages. The symptoms range from comparatively minor illusions, vivid dreams, and occasional, non-disturbing visual hallucinations to frank psychosis. The pathogenesis of psychosis in PD is not fully known. Management of psychosis in PD requires a multidisciplinary approach. Some of the newer atypical antipsychotics are effective against psychosis with no significant worsening of PD. Psychosis in PD is associated with poor quality of life for patients and the carers.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16210460      PMCID： PMC1743370          DOI： 10.1136/pgmj.2004.032029

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


  25 in total

1.  Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease.

Authors:  Joseph Bergman; Vladimir Lerner
Journal:  Clin Neuropharmacol       Date:  2002 Mar-Apr       Impact factor: 1.592

2.  Hallucinosis in idiopathic Parkinson's disease.

Authors:  J M Graham; R A Grünewald; H J Sagar
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-10       Impact factor: 10.154

3.  Risk factors for nursing home placement in advanced Parkinson's disease.

Authors:  C G Goetz; G T Stebbins
Journal:  Neurology       Date:  1993-11       Impact factor: 9.910

Review 4.  Visual hallucinations in Parkinson's disease: a review and phenomenological survey.

Authors:  J Barnes; A S David
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-06       Impact factor: 10.154

5.  Visual hallucinations associated with Parkinson disease.

Authors:  J R Sanchez-Ramos; R Ortoll; G W Paulson
Journal:  Arch Neurol       Date:  1996-12

6.  Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series.

Authors:  R Bullock; A Cameron
Journal:  Curr Med Res Opin       Date:  2002       Impact factor: 2.580

7.  Rebound psychosis: effect of discontinuation of antipsychotics in Parkinson's disease.

Authors:  Hubert H Fernandez; Martha E Trieschmann; Michael S Okun
Journal:  Mov Disord       Date:  2005-01       Impact factor: 10.338

8.  Psychotic symptoms in Parkinson's disease patients with dementia.

Authors:  D Naimark; E Jackson; E Rockwell; D V Jeste
Journal:  J Am Geriatr Soc       Date:  1996-03       Impact factor: 5.562

9.  Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: a cautionary note.

Authors:  J M Graham; J D Sussman; K S Ford; H J Sagar
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-11       Impact factor: 10.154

10.  [Electroconvulsive therapy in comorbidity of treatment refractory paranoid hallucinatory psychoses with Parkinson disease].

Authors:  G Höflich; K W Burghof; S Kasper; H J Möller
Journal:  Nervenarzt       Date:  1994-03       Impact factor: 1.214
View more
  12 in total

1.  Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis.

Authors:  Daniel Weintraub; Peijun Chen; Rosalinda V Ignacio; Eugenia Mamikonyan; Helen C Kales
Journal:  Arch Neurol       Date:  2011-07

2.  MitoPark mice, an animal model of Parkinson's disease, show enhanced prepulse inhibition of acoustic startle and no loss of gating in response to the adenosine A(2A) antagonist SCH 412348.

Authors:  Steven M Grauer; Robert Hodgson; Lynn A Hyde
Journal:  Psychopharmacology (Berl)       Date:  2013-10-23       Impact factor: 4.530

Review 3.  Psychosis in Parkinson Disease: A Review of Etiology, Phenomenology, and Management.

Authors:  Niyatee Samudra; Neepa Patel; Kyle B Womack; Pravin Khemani; Shilpa Chitnis
Journal:  Drugs Aging       Date:  2016-12       Impact factor: 3.923

Review 4.  Drug-induced parkinsonism in the elderly: incidence, management and prevention.

Authors:  José Luis López-Sendón; María Angeles Mena; Justo García de Yébenes
Journal:  Drugs Aging       Date:  2012-02-01       Impact factor: 3.923

5.  Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies.

Authors:  Sarah Horn; Hayley Richardson; Sharon X Xie; Daniel Weintraub; Nabila Dahodwala
Journal:  Parkinsonism Relat Disord       Date:  2019-11-11       Impact factor: 4.891

6.  Schizophrenia with Comorbid Idiopathic Parkinson's Disease: A Difficult Clinical Management Scenario.

Authors:  Sandeep Grover; Swapnajeet Sahoo; Manoj Kumar Goyal
Journal:  Indian J Psychol Med       Date:  2017 Nov-Dec

7.  Medical mimics: Differential diagnostic considerations for psychiatric symptoms.

Authors:  Jerry McKee; Nancy Brahm
Journal:  Ment Health Clin       Date:  2016-11-03

8.  Development of Parkinsonism following exposure to aripiprazole: two case reports.

Authors:  Lannah L Lua; Lin Zhang
Journal:  J Med Case Rep       Date:  2009-03-10

Review 9.  Auditory hallucinations in those populations that do not suffer from schizophrenia.

Authors:  C Choong; M D Hunter; P W R Woodruff
Journal:  Curr Psychiatry Rep       Date:  2007-06       Impact factor: 8.081

Review 10.  Management of Psychosis in Parkinson's Disease: Emphasizing Clinical Subtypes and Pathophysiological Mechanisms of the Condition.

Authors:  Raquel N Taddei; Seyda Cankaya; Sandeep Dhaliwal; K Ray Chaudhuri
Journal:  Parkinsons Dis       Date:  2017-09-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.